BMS 182566
Latest Information Update: 16 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)
- 28 Mar 1995 Preclinical development for Cancer in USA (Unknown route)